Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Exp Clin Cancer Res ; 22(3): 411-8, 2003 Sep.
Article in English | MEDLINE | ID: mdl-14582700

ABSTRACT

Naphthalmustine, 2-[2-[bis-(2-chloroethyl)amino]ethyl]-1H-benz[de]isoquinoline-1,3-dione (Compound 1) has been synthesized as a rationally designed new anticancer agent from N-(2-bromoethyl)naphthalimide. Its chemical alkylating activity exceeded that of nor-HN2 used as standard compound for comparison. Its antitumour efficacy was assessed in vivo in two murine ascites tumours namely Sarcoma-180 (S-180) and Ehrlich ascites carcinoma (EAC) by measuring the increase in median survival times (MST) of drug treated (T) over untreated control (C) mice. The clinical drug cyclophosphamide and the experimental compound mitonafide were used as positive controls for comparison. Compound 1 has displayed substantial and reproducible antitumoural activity in these tumours since very high remission times of treated animals were observed. Significant increase in the life span of mice bearing highly advanced tumour for 10 days before the drug challenge was also noted after its treatment. Its LD50 value was 200 mg/Kg by single i.p. injection. Its toxicity was also assessed in vivo in normal and in S-180 bearing mice by measuring drug-induced changes in hematological parameters, femoral bone marrow and splenic cellularity sequentially on days 9, 15 and 21 following drug treatment at the optimum dose of 12 mg/kg from day 1 to 7. The results indicated that the compound did not adversely affect hematopoiesis. Drug-induced hepatotoxicity and nephrotoxicity were also evaluated on those days but no such toxicities were detected. Naphthalmustine inhibits the synthesis of DNA and RNA in S-180 tumour cells. It was further screened in vitro in 4 different human tumour cell lines but no significant activity was observed in those lines.


Subject(s)
Antineoplastic Agents, Alkylating/chemical synthesis , Antineoplastic Agents, Alkylating/therapeutic use , Drug Design , Isoquinolines/chemical synthesis , Isoquinolines/therapeutic use , Nitrogen Mustard Compounds/chemical synthesis , Nitrogen Mustard Compounds/therapeutic use , Animals , Antineoplastic Agents, Alkylating/adverse effects , Antineoplastic Agents, Alkylating/pharmacology , Cell Division/drug effects , Cell Line, Tumor , Humans , Isoquinolines/adverse effects , Isoquinolines/pharmacology , Male , Mice , Molecular Structure , Neoplasm Transplantation , Nitrogen Mustard Compounds/adverse effects , Nitrogen Mustard Compounds/pharmacology , Survival Rate
2.
Planta Med ; 69(2): 164-6, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12624825

ABSTRACT

Two new elemanolides, epivernodalol and lasiopulide, were isolated after chromatographic separation of the alcoholic extract of the dried aerial parts of the Vernonia lasiopus. These elemanolides are new C-10 epimers of the sesquiterpene lactones vernodalol and demethylacroylated vernodalol isolated from other species of Vernonia. Both elemanolides showed in vitro cytotoxicity against human cancer cell lines in culture. This is the first report of isolation and cytotoxic activity of the two elemanolides from V. lasiopus.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Phytotherapy , Plant Extracts/pharmacology , Sesquiterpenes/pharmacology , Vernonia , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/therapeutic use , HT29 Cells/drug effects , Humans , Inhibitory Concentration 50 , Magnetic Resonance Spectroscopy , Plant Extracts/administration & dosage , Plant Extracts/chemistry , Plant Extracts/therapeutic use , Sesquiterpenes/administration & dosage , Sesquiterpenes/isolation & purification
3.
Acta Pol Pharm ; 60(4): 285-91, 2003.
Article in English | MEDLINE | ID: mdl-14714857

ABSTRACT

Bromonapmustine 4a and chloronapmustine 4b, two new nitrogen mustards of substituted naphthalimides, have been synthesized as mixed-function anticancer compounds from 4-bromo- and 4-chloro-N-(2-hydroxyethyl)-naphthalimide respectively following a three-step process. Their chemical alkylating activity exceeded that of nor-HN2. Their antitumour efficacy were assessed in vivo in two murine ascites tumours, namely Ehrlich ascites carcinoma (EAC) and Sarcoma-180 (S-180) by measuring the increase in median survival times (MST) of drug treated (T) over untreated control (C) mice. Two standard clinical drugs, namely endoxan (cyclophosphamide) and 5-fluorouracil (5-FU) were used as positive controls for comparison. Both of them have displayed substantial and reproducible antitumoural activity in these tumours comparable with 5-FU. These compounds inhibit the synthesis of DNA and RNA in S-180 tumour cells. These were further screened in vitro in 3 different human tumour cell lines but no significant activity was observed in those lines.


Subject(s)
Antineoplastic Agents/chemical synthesis , Imides/chemical synthesis , Nitrogen Mustard Compounds/chemical synthesis , Antineoplastic Agents/pharmacology , Antineoplastic Agents, Alkylating/chemical synthesis , Antineoplastic Agents, Alkylating/pharmacology , Cell Line, Tumor , Chromatography, High Pressure Liquid , Chromatography, Thin Layer , DNA, Neoplasm/biosynthesis , Drug Design , Drug Screening Assays, Antitumor , Humans , Imides/pharmacology , Nitrogen Mustard Compounds/pharmacology , RNA, Neoplasm/biosynthesis , Spectrophotometry, Infrared , Spectrophotometry, Ultraviolet , Spectroscopy, Fourier Transform Infrared
SELECTION OF CITATIONS
SEARCH DETAIL
...